Treatment options after tumor resistance: exploiting vulnerabilities from genome to tumor microenvironment

Most advanced cancers eventually develop therapeutic resistance, often considered as a clinical endpoint but can be interpreted as an evolutionary state that exposes newly acquired dependencies and therefore creates a rationale for vulnerability-based treatment after standard options fail. This review summarizes resistance-associated vulnerabilities across genomic, epigenomic, signaling, cellular, and microenvironmental layers. At the genomic level, homologous recombination deficiency, deficient mismatch repair, chromosomal instability, and replication stress can inform DNA repair-directed, checkpoint-targeting, or immune-based strategies with different clinical evidence levels. At the epigenomic level, we propose chromatin-state maintenance vulnerability as an organizing concept describing adaptive dependence on chromatin-regulatory programs sustaining resistant phenotypes. This concept shifts epigenetic targeting away from isolated epigenetic marks to the machinery required to maintain a resistant phenotype. Compensatory signaling creates dependencies on specific network nodes, providing a rationale for combinations that suppress the pathways required for resistant-cell survival. Cancer stemness links molecular adaptations to persistent disease; interactions with a therapy-remodeled microenvironment create opportunities for intervention beyond direct tumor-cell killing. In this setting, therapeutic vulnerability may lie in reprogramming the surrounding ecosystem to restore antitumor immunity and treatment responsiveness. Additionally, we propose the concept of operational vulnerability biomarkers as measurements linked to a treatment-relevant dependency or functional susceptibility and a prespecified therapeutic decision. This decision-oriented framework complements established functional and dynamic biomarker concepts. By connecting resistant states with measurable dependencies, matched interventions, and clinical-trial strategies, the review provides a practical framework for developing and testing rational subsequent-line treatments while addressing the biological, analytical, and practical barriers to implementation.